Global Venturing Review

The Big Ones 2020 has been a year when, for obvious reasons, innovative drug development has taken a leap forward. Tempus combines artificial intelligence and molecular data to come up with precision therapeutics, and has secured $200m in series G2 funding from investors including Novo and Google at an $8.1bn post-money valuation. That’s a 62% … Continue reading "14 December 2020 – Drug Development Company Tempus Secures $200m"